Looking at sixty - seven recent
drug discovery projects based
on preclinical cancer biology research, they found that in more than 75 percent of cases the published data did not match up with their in - house attempts to replicate.
These forward - looking statements are based
on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct
preclinical development of its
drug candidates and advance such candidates into clinical development, achieve its operational objectives, obtain patent protection for its
discoveries and establish strategic alliances, as well as those relating to manufacturing, the regulatory process, intellectual property rights, and the therapeutic or commercial value of its
drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward - looking statements.